US7417038B1
(en)
|
1998-10-15 |
2008-08-26 |
Imperial Innovations Limited |
Methods of treating cachexia
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
ES2387881T3
(es)
*
|
2004-03-16 |
2012-10-03 |
Boehringer Ingelheim International Gmbh |
Derivados de benceno sustituidos por glucopiranosilo, medicamentos que contienen estos compuestos, su uso y procedimiento para su preparación
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
UA91546C2
(ru)
*
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛЛИЧЕСКАЯ ФОРМА 1-ХЛОР-4-(b-D-ГЛЮКОПИРАНОЗ-1- ИЛ)-2-[4-((S)- ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛА, СПОСОБ ЕЕ ПОЛУЧЕНИЯ И ЕЕ ПРИМЕНЕНИЕ ПРИ ПРИГОТАВЛЕНИИ ЛЕКАРСТВЕННЫХ СРЕДСТВ
|
US7772191B2
(en)
*
|
2005-05-10 |
2010-08-10 |
Boehringer Ingelheim International Gmbh |
Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
AU2006289093A1
(en)
*
|
2005-09-08 |
2007-03-15 |
Boehringer Ingelheim International Gmbh |
Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
|
PE20080697A1
(es)
*
|
2006-05-03 |
2008-08-05 |
Boehringer Ingelheim Int |
Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
CA2810522A1
(en)
|
2006-05-04 |
2007-11-15 |
Boehringer Ingelheim International Gmbh |
Polymorphs
|
EP2054426A1
(en)
*
|
2006-08-15 |
2009-05-06 |
Boehringer Ingelheim International GmbH |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
|
US8283326B2
(en)
*
|
2006-10-27 |
2012-10-09 |
Boehringer Ingelheim International Gmbh |
Crystalline form of 4-(beta-D-glucopyranos-1-yl)-1-methyl-2-[4-((S)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
|
GB0624282D0
(en)
|
2006-12-05 |
2007-01-10 |
Cavalla David |
Treatment of cachexia
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
CL2008002427A1
(es)
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
|
LT2200606T
(lt)
|
2007-09-10 |
2017-12-27 |
Janssen Pharmaceutica, N.V. |
Junginių, naudingų kaip sglt inhibitoriai, gamybos būdas
|
US8648085B2
(en)
|
2007-11-30 |
2014-02-11 |
Boehringer Ingelheim International Gmbh |
1, 5-dihydro-pyrazolo (3, 4-D) pyrimidin-4-one derivatives and their use as PDE9A mudulators for the treatment of CNS disorders
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
AR071175A1
(es)
|
2008-04-03 |
2010-06-02 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
|
EP2291189B1
(en)
*
|
2008-05-22 |
2014-10-01 |
AstraZeneca AB |
Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
BRPI0916997A2
(pt)
|
2008-08-06 |
2020-12-15 |
Boehringer Ingelheim International Gmbh |
Inibidor de dpp-4 e seu uso
|
US9079905B2
(en)
|
2008-09-08 |
2015-07-14 |
Boehringer Ingelheim International Gmbh |
Compounds for the treatment of CNS disorders
|
EP2344195A2
(en)
|
2008-09-10 |
2011-07-20 |
Boehringer Ingelheim International GmbH |
Combination therapy for the treatment of diabetes and related conditions
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
US9056850B2
(en)
|
2008-10-17 |
2015-06-16 |
Janssen Pharmaceutica N.V. |
Process for the preparation of compounds useful as inhibitors of SGLT
|
JP2012512848A
(ja)
|
2008-12-23 |
2012-06-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
有機化合物の塩の形態
|
AR074990A1
(es)
|
2009-01-07 |
2011-03-02 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
|
DK2395968T3
(da)
|
2009-02-13 |
2024-03-04 |
Boehringer Ingelheim Int |
Farmaceutisk sammensætning omfattende glucopyranosyldiphenylmethanderivater, farmaceutisk doseringsform deraf, fremgangsmåde til deres forberedelse og anvendelser deraf til forbedret glykæmisk kontrol hos en patient
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
EA022349B1
(ru)
|
2009-02-13 |
2015-12-30 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Фармацевтическая композиция, включающая ингибитор sglt2, ингибитор дпп-iv и другой антидиабетический агент, и ее применение
|
CN102316875A
(zh)
*
|
2009-02-13 |
2012-01-11 |
贝林格尔.英格海姆国际有限公司 |
用于治疗i型糖尿病、ii型糖尿病、葡萄糖耐量降低或高血糖症的sglt-2抑制剂
|
UY32531A
(es)
|
2009-03-31 |
2010-10-29 |
Boehringer Ingelheim Int |
Nuevos compuestos para el tratamiento de trastornos del snc
|
EP2601949B1
(en)
*
|
2009-04-16 |
2014-10-29 |
Taisho Pharmaceutical Co., Ltd. |
Pharmaceutical compositions with (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol and an insulin secretagogue.
|
WO2010147430A2
(en)
*
|
2009-06-19 |
2010-12-23 |
Green Cross Corporation |
Novel c-aryl glucoside sglt2 inhibitors and pharmaceutical composition comprising same
|
US20110009347A1
(en)
*
|
2009-07-08 |
2011-01-13 |
Yin Liang |
Combination therapy for the treatment of diabetes
|
EP2451797B1
(en)
|
2009-07-10 |
2013-04-03 |
Janssen Pharmaceutica, N.V. |
CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE
|
PL2483286T3
(pl)
|
2009-09-30 |
2017-04-28 |
Boehringer Ingelheim International Gmbh |
Sposób wytwarzania postaci krystalicznej 1-chloro-4-(β-D-glukopiranoz-1-ylo)-2-[4-((S)-tetrahydrofuran-3-yloksy)-benzylo]-benzenu
|
KR101813025B1
(ko)
*
|
2009-09-30 |
2017-12-28 |
베링거 인겔하임 인터내셔날 게엠베하 |
글루코피라노실치환된 벤질벤젠 유도체의 제조방법
|
UY32919A
(es)
*
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
|
KR101730920B1
(ko)
|
2009-10-14 |
2017-04-27 |
얀센 파마슈티카 엔.브이. |
Sglt2의 억제제로서 유용한 화합물의 제조 방법
|
SI2496583T1
(sl)
|
2009-11-02 |
2015-02-27 |
Pfizer Inc. |
Derivati dioksa-biciklo(3.2.1)oktan-2,3,4-triola
|
US8871264B2
(en)
|
2009-11-13 |
2014-10-28 |
Astrazeneca Ab |
Immediate release tablet formulations
|
BR112012012641A2
(pt)
|
2009-11-27 |
2020-08-11 |
Boehringer Ingelheim International Gmbh |
TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
WO2011120923A1
(en)
|
2010-03-30 |
2011-10-06 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
|
CA2797310C
(en)
|
2010-05-05 |
2020-03-31 |
Boehringer Ingelheim International Gmbh |
Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
|
DK2568988T3
(en)
|
2010-05-11 |
2016-08-22 |
Janssen Pharmaceutica Nv |
Pharmaceutical formulations comprising 1- (BETA-D-glucopyranosyl) -2-THIENYLMETHYLBENZEN derivatives as inhibitors of SGLT
|
US8933024B2
(en)
|
2010-06-18 |
2015-01-13 |
Sanofi |
Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
AU2011268940B2
(en)
|
2010-06-24 |
2015-05-21 |
Boehringer Ingelheim International Gmbh |
Diabetes therapy
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
UA110347C2
(ru)
|
2010-08-12 |
2015-12-25 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
Производные 6-циклоалкил-1,5-дигидропиразоло [3,4-d] пиримидин-4-ону и их применение в качестве ингибиторов pde9a
|
WO2012025857A1
(en)
|
2010-08-23 |
2012-03-01 |
Hetero Research Foundation |
Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
|
WO2012041898A1
(en)
|
2010-09-29 |
2012-04-05 |
Celon Pharma Sp. Z O.O. |
Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
|
US20120283169A1
(en)
*
|
2010-11-08 |
2012-11-08 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
AR083878A1
(es)
|
2010-11-15 |
2013-03-27 |
Boehringer Ingelheim Int |
Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
|
US20130035281A1
(en)
|
2011-02-09 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
UY33937A
(es)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
|
JP5973551B2
(ja)
|
2011-04-13 |
2016-08-23 |
ヤンセン ファーマシューティカ エヌ.ベー. |
Sglt2の阻害物質として有用な化合物の調製プロセス
|
TWI542596B
(zh)
|
2011-05-09 |
2016-07-21 |
健生藥品公司 |
(2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
|
EP2714052B1
(en)
*
|
2011-06-03 |
2018-09-19 |
Boehringer Ingelheim International GmbH |
Sglt-2 inhibitors for treating metabolic disorders in patients treated with neuroleptic agents
|
US20130035298A1
(en)
*
|
2011-07-08 |
2013-02-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
CN102863417B
(zh)
*
|
2011-07-09 |
2015-01-14 |
山东轩竹医药科技有限公司 |
C-糖苷衍生物
|
US8962636B2
(en)
|
2011-07-15 |
2015-02-24 |
Boehringer Ingelheim International Gmbh |
Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US9192617B2
(en)
*
|
2012-03-20 |
2015-11-24 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
EP2849755A1
(en)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
PL2981269T3
(pl)
|
2013-04-04 |
2024-02-05 |
Boehringer Ingelheim Vetmedica Gmbh |
Leczenie zaburzeń metabolicznych u zwierząt koniowatych
|
CA2812519A1
(en)
*
|
2013-04-05 |
2014-10-05 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
PT2981271T
(pt)
|
2013-04-05 |
2019-02-19 |
Boehringer Ingelheim Int |
Utilizações terapêuticas de empagliflozina
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
EP4000608A1
(en)
|
2013-04-18 |
2022-05-25 |
Boehringer Ingelheim International GmbH |
Pharmaceutical composition, methods for treating and uses thereof
|
CA3163455A1
(en)
|
2013-12-17 |
2015-06-25 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in feline animals
|
WO2015101916A1
(en)
|
2013-12-30 |
2015-07-09 |
Mylan Laboratories Ltd. |
Process for the preparation of empagliflozin
|
AU2015208291B2
(en)
|
2014-01-23 |
2019-12-05 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in canine animals
|
WO2015128453A1
(en)
|
2014-02-28 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Medical use of a dpp-4 inhibitor
|
NZ723781A
(en)
|
2014-04-01 |
2022-09-30 |
Boehringer Ingelheim Vetmedica Gmbh |
Treatment of metabolic disorders in equine animals
|
CA2956257C
(en)
|
2014-09-25 |
2022-07-12 |
Boehringer Ingelheim Vetmedica Gmbh |
Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
|
US20170319539A1
(en)
*
|
2014-10-01 |
2017-11-09 |
Mylan Laboratories Ltd. |
Amorphous Empagliflozin
|
AU2016229982B2
(en)
|
2015-03-09 |
2020-06-18 |
Intekrin Therapeutics, Inc. |
Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
|
US20170071970A1
(en)
|
2015-09-15 |
2017-03-16 |
Janssen Pharmaceutica Nv |
Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
|
WO2017064193A1
(en)
|
2015-10-15 |
2017-04-20 |
Boehringer Ingelheim International Gmbh |
Sglt-2 inhibitor for use in the treatment of a metabolic myopathy
|
EP4233840A3
(en)
|
2016-06-10 |
2023-10-18 |
Boehringer Ingelheim International GmbH |
Combinations of linagliptin and metformin
|
JP2020515639A
(ja)
|
2017-04-03 |
2020-05-28 |
コヒラス・バイオサイエンシズ・インコーポレイテッド |
進行性核上性麻痺の処置のためのPPARγアゴニスト
|
KR102204439B1
(ko)
|
2018-05-14 |
2021-01-18 |
에이치케이이노엔 주식회사 |
Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
|
US20210212991A1
(en)
*
|
2018-05-31 |
2021-07-15 |
Hua Medicine (Shanghai) Ltd. |
Pharmaceutical combination containing glucose kinase activator and ppar receptor activator, composition, compound preparaton method for same, and uses thereof
|
WO2020039394A1
(en)
|
2018-08-24 |
2020-02-27 |
Novartis Ag |
New drug combinations
|
CN110141555A
(zh)
*
|
2019-06-21 |
2019-08-20 |
江苏豪森药业集团有限公司 |
一种恩格列净片及其制备方法
|
JP7299408B2
(ja)
*
|
2019-07-26 |
2023-06-27 |
ドンバオ パープル スター (ハンチョウ) バイオファーマシューティカル シーオー.,エルティーディー. |
SGLTs/DPP4阻害剤およびその使用
|
US11759474B2
(en)
|
2019-11-28 |
2023-09-19 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of SGLT-2 inhibitors in the drying-off of non-human mammals
|
AU2021222297A1
(en)
|
2020-02-17 |
2022-08-04 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of SGLT-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
|
CA3173808A1
(en)
|
2020-03-06 |
2021-09-10 |
Vertex Pharmaceuticals Incorporated |
Methods of treating apol-1 dependent focal segmental glomerulosclerosis
|
WO2022051316A1
(en)
|
2020-09-03 |
2022-03-10 |
Coherus Biosciences, Inc. |
Fixed dose combinations of chs-131 and a sglt-2 inhibitor
|
CN112206216B
(zh)
*
|
2020-10-15 |
2023-03-17 |
江西华士药业有限公司 |
一种缓释达格列净的制备方法
|
KR20230001000A
(ko)
|
2021-06-25 |
2023-01-03 |
(주)휴온스 |
약물방출 특성이 개선된 엠파글리플로진 및 메트포르민 복합제제
|
JP2024525981A
(ja)
|
2021-07-28 |
2024-07-12 |
ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー |
ヒト以外の哺乳動物における腎疾患の予防及び/又は治療のためのsglt-2阻害剤の使用
|
EP4376819A1
(en)
|
2021-07-28 |
2024-06-05 |
Boehringer Ingelheim Vetmedica GmbH |
Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
|
AU2022319909A1
(en)
|
2021-07-28 |
2024-02-22 |
Boehringer Ingelheim Vetmedica Gmbh |
Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
|
WO2023227492A1
(en)
|
2022-05-25 |
2023-11-30 |
Boehringer Ingelheim Vetmedica Gmbh |
Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
|
KR102490653B1
(ko)
*
|
2022-08-03 |
2023-01-20 |
진양제약주식회사 |
다파글리플로진 및 글리메피리드를 포함하는 약제학적 조성물
|